Advisor Group’s Travere Therapeutics TVTX Stock Holding History

Advisor Group’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$14K	Sell	958 -639	-40%	-$8.16K	﹤0.01%	4156
2019 Q3	$19K	Buy	1,597 +194	+14%	+$3.21K	﹤0.01%	3998
2019 Q2	$29K	Sell	1,403 -40	-3%	-$790	﹤0.01%	3731
2019 Q1	$33K	Buy	1,443 +1,368	+1,824%	+$30.2K	﹤0.01%	3670
2018 Q4	$2K	Buy	+75	New	+$1.87K	﹤0.01%	4855
2018 Q3	–	Sell	-57	Closed	-$2K	–	5223
2018 Q2	$2K	Sell	57 -20	-26%	-$533	﹤0.01%	4703
2018 Q1	$1K	Hold	77	–	–	﹤0.01%	4861
2017 Q4	$1K	Hold	77	–	–	﹤0.01%	4861
2017 Q3	$1K	Buy	77 +57	+285%	+$1.25K	﹤0.01%	4728
2017 Q2	$0	Hold	20	–	–	﹤0.01%	4911
2017 Q1	$0	Hold	20	–	–	﹤0.01%	4804
2016 Q4	$0	Hold	20	–	–	﹤0.01%	4619
2016 Q3	$0	Hold	20	–	–	﹤0.01%	4615
2016 Q2	$0	Buy	+20	New	+$324	﹤0.01%	4503

Other funds holding TVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Advisor Group's TVTX Position: Q4 2019 in Review

Advisor Group reduced its Travere Therapeutics (TVTX) stake by 40% in Q4 2019, selling an estimated $8.16K and leaving 958 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #4156.

Advisor Group first reported a position in TVTX in Q2 2016 and has held it in 14 quarters since. The position peaked at $33K in Q1 2019. 131 funds tracked by Wall St. Rank hold TVTX as of Q4 2019.

Advisor Group held 958 shares of Travere Therapeutics worth $14K as of Q4 2019.
Advisor Group sold 639 Travere Therapeutics shares in Q4 2019, an estimated $8.16K.
Travere Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4156 holding.
Advisor Group first reported a position in Travere Therapeutics in Q2 2016 and has held it in 14 quarters since.
Advisor Group's Travere Therapeutics position peaked at $33K in Q1 2019.
131 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.